Related Experiment Videos
Subareolar injection of 99mTc facilitates sentinel lymph node identification
Todd M Tuttle1, Marybeth Colbert, Robert Christensen
1Department of Surgery, Park Nicollet Clinic, Minneapolis, Minnesota, USA. tutt1006@umn.edu
Annals of Surgical Oncology
|February 7, 2002
Summary
Subareolar injection of technetium improves sentinel lymph node (SLN) identification rates in breast cancer patients. This technique offers a simpler and more accurate method compared to standard intraparenchymal injections, potentially reducing variability in results.
Area of Science:
- Oncology
- Surgical Pathology
- Nuclear Medicine
Background:
- Sentinel lymph node (SLN) biopsy is an alternative to axillary dissection for breast cancer.
- Standard intraparenchymal injection for SLN biopsy has variable identification and false-negative rates.
- The subareolar location has a rich lymphatic network, suggesting its potential for injection.
Purpose of the Study:
- To evaluate the efficacy of subareolar injection of technetium for sentinel lymph node identification in breast cancer patients.
- To compare the accuracy and reliability of subareolar injection with the standard intraparenchymal method.
Main Methods:
- 159 SLN biopsy procedures were performed on 158 breast cancer patients between August 1999 and December 2000.
- 99mTc-labeled sulfur colloid was injected into the subareolar location for each patient.
- 1% isosulfan blue dye was administered via intraparenchymal injection concurrently.
Main Results:
- Subareolar injection of technetium successfully identified a radioactive SLN in 100% of cases.
- A blue SLN was identified in 97% of cases.
- 98% concordance was observed between radioactive and blue SLNs, indicating shared lymphatic drainage.
Conclusions:
- Subareolar injection of technetium significantly enhances SLN identification rates in breast cancer.
- This technique offers improved simplicity and accuracy, potentially mitigating the variability associated with standard intraparenchymal injections.